Fed. Circ. Upholds GSK Win Over Avodart Patent

Law360, New York (February 24, 2014, 4:49 PM EST) -- The Federal Circuit on Monday upheld a Delaware district court's ruling that Banner Pharmacaps Inc., Mylan Pharmaceuticals Inc. and other generic-drug makers failed to prove that a patent owned by British pharmaceutical company GlaxoSmithKline LLC for the prostate reduction pill Avodart was invalid. 

The three-judge panel rejected arguments by Banner, Mylan, Roxane Laboratories Inc., Watson Laboratories Inc. and Impax Laboratories Inc. that U.S. Patent Number 5,565,467 failed to adequately describe a chemical compound known as a “solvate” in dutasteride, the generic name for the Avodart drug....
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

GlaxoSmithKline LLC v. Banner Pharmacaps, Inc.


Case Number

13-1593

Court

Appellate - Federal Circuit

Nature of Suit

830 Patent Infringement (Fed. Question)

Date Filed

August 29, 2013


Case Title

GlaxoSmithKline LLC v. Banner Pharmacaps, Inc.


Case Number

13-1594

Court

Appellate - Federal Circuit

Nature of Suit

830 Patent Infringement (Fed. Question)

Date Filed

August 29, 2013


Case Title

GlaxoSmithKline LLC v. Banner Pharmacaps, Inc.


Case Number

13-1595

Court

Appellate - Federal Circuit

Nature of Suit

830 Patent Infringement (Fed. Question)

Date Filed

August 29, 2013


Case Title

GlaxoSmithKline LLC v. Banner Pharmacaps, Inc.


Case Number

13-1598

Court

Appellate - Federal Circuit

Nature of Suit

830 Patent Infringement (Fed. Question)

Date Filed

August 30, 2013

Law Firms

Companies

Government Agencies

Patents